Skip to main content
  • Home
  • About
  • Faculty Experts
  • For The Media
  • Videos
  • Topics
    • Alumni
    • Events
    • Faculty
    • Library
    • Research
    • Students
    • All Topics
  • Contact
  • Submit
STEM
  • All News
  • Arts & Culture
  • Business & Economy
  • Campus & Community
  • Health & Society
  • Media, Law & Policy
  • STEM
  • Veterans
  • |
  • Alumni
  • The Peel
  • Athletics
Sections
  • All News
  • Arts & Culture
  • Business & Economy
  • Campus & Community
  • Health & Society
  • Media, Law & Policy
  • STEM
  • Veterans
  • |
  • Alumni
  • The Peel
  • Athletics
  • Home
  • About
  • Faculty Experts
  • For The Media
  • Videos
  • Topics
    • Alumni
    • Events
    • Faculty
    • Library
    • Research
    • Students
    • All Topics
  • Contact
  • Submit
STEM

Chemist Develops Potential Drug to Treat Type 2 Diabetes Without Harsh Side Effects

Sunday, July 12, 2020, By Dan Bernardi
Share
BioInspiredCollege of Arts and SciencesfacultyresearchSTEM
head shot

Robert P. Doyle

Robert P. Doyle, the Laura J. and L. Douglas Meredith Professor in the Department of Chemistry in the College of Arts and Sciences and adjunct associate professor of medicine at SUNY Upstate Medical University, has developed a new drug lead to treat type 2 diabetes in millions of patients who are seeking to better control their blood sugar without the common side effects of nausea, vomiting and, in select cases, undesired weight loss. His research article, “Corrination of a GLP-1 Receptor Agonist for Glycemic Control without Emesis,” has been published in the prestigious journal Cell Reports.

A common group of drugs used to treat type 2 diabetes are glucagon-like peptide-1 receptor (GLP-1R) agonists. While they do lower blood sugar levels in diabetic patients, their side effects include nausea, vomiting and weight loss.

Through a grant from the National Institutes of Health (NIH), Doyle and his team found a way to combine two molecules into a new substance that so far seems to lower blood sugar without those undesired side effects.

In technical terms, the team developed a new area of bioconjugation—a chemical technique used to couple two molecules. By binding together exendin-4 (Ex4), an FDA-approved GLP-1R agonist, to dicyanocobinamide (Cbi), which is a small piece of the complex vitamin B12 molecule, they produced Cbi-Ex4 in a technique they call “corrination.”

Data collected from testing Cbi-Ex4 in the musk shrew (Suncus murinus), the mammal used in this study due to its ability to vomit (rodents and many mammals lack that ability), revealed beneficial effects as evidenced by improved blood sugar levels during glucose tolerance tests and a profound reduction in vomiting compared to Ex4. Importantly, no weight loss was noted, again in stark contrast to the currently approved GLP-1R agonist, making this new drug ideal for patients who require glucoregulation without affecting their body mass index (BMI) levels. This drug could therefore benefit diabetes patients who also live with cystic fibrosis, COPD, sarcopenia, cancer or HIV, where weight-loss is counter-indicated.

The next step in the development of this groundbreaking drug is to move it through the pre-clinical phase into phase I human studies. Doyle and his team have submitted a new grant proposal to the NIH to fund this effort.

Doyle’s research was conducted in collaboration with the labs of Matt Hayes, professor in the Department of Psychiatry, University of Pennsylvania, and Bart C. De Jonghe, professor in the Department of Biobehavioral Health Sciences, University of Pennsylvania.

  • Author

Dan Bernardi

  • Recent
  • Important Information Regarding Proof of Eligibility for and Access to the COVID Vaccine
    Saturday, January 16, 2021, By News Staff
  • COVID-19 Update: Vaccination | Testing | Important Reminders | Zoom Sessions
    Friday, January 15, 2021, By News Staff
  • Important Update: Spring 2021 Pre-Arrival Testing Requirements (Students from New York State and contiguous states)
    Thursday, January 14, 2021, By News Staff
  • Important Update: Spring 2021 Pre-Arrival Testing and Quarantine Requirements (Students from all states non-contiguous to New York State and international locations)
    Thursday, January 14, 2021, By News Staff
  • Students and Families Invited to Participate in Zoom Sessions to Discuss Return to Campus Planning
    Thursday, January 14, 2021, By News Staff

More In STEM

The Role of Digital Forensics and Tracking Down US Capitol Riot Criminals

With just under a week left before President-elect Joe Biden’s inauguration ceremony, investigators and law enforcement agencies across the country are working speedily to identify as many of the Jan. 6 U.S. Capitol riot offenders as they can. Knowing exactly…

A&S Researchers Awarded $2.1M Grant to Study Causes of Congenital Heart Defects

Congenital heart defects are the most common type of birth defect, affecting nearly 1 percent of births in the United States each year, according to the Centers for Disease Control and Prevention. Doctors have been unable to lower that number…

$1.5 Million NIH Grant Funds ALS-Linked Research

The human body is made up of trillions of cells. Within each cell are proteins which help to maintain the structure, function and regulation of the body’s tissues and organs. When cells are under stress, as in response to heat…

Professor Shikha Nangia Selected as Associate Editor for ACS Applied Bio Materials Journal

Biomedical and chemical engineering Professor Shikha Nangia was selected as the associate editor for the ACS Applied Bio Materials journal. ACS Applied Bio Materials is an interdisciplinary journal publishing original research covering all aspects of biomaterials and biointerfaces including and beyond…

It’s Getting Hot In Here: Warming World Will Fry Power Plant Production in Coming Years

There’s no doubt the Earth’s temperatures are going up. According to a December report by the World Meteorological Organization, 2020 is on track to be one of the three hottest years on record, already within the warmest decade to date….

Subscribe to SU Today

If you need help with your subscription, contact sunews@syr.edu.

Connect With Us

  • Twitter
  • Facebook
  • Instagram
  • Youtube
  • LinkedIn
Social Media Directory

For the Media

Find an Expert Follow @SyracuseUNews
  • Facebook
  • Instagram
  • Youtube
  • LinkedIn
  • @SyracuseU
  • @SyracuseUNews
  • @SUCampus
  • Social Media Directory
  • Accessibility
  • Privacy
  • Campus Status
  • Syracuse.edu
© 2021 Syracuse University News. All Rights Reserved.